Sign In
Buy RHHBY
$54.64
-0.630 (-1.14%)
At Close: Jul 31, 2026
Roche announces the upcoming launch of the SARS-CoV-2 Rapid Antigen Test Nasal allowing for patient self-collection
11:25am, Monday, 01'st Feb 2021
Basel, 01 February 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced it has obtained the CE mark for its new SARS-CoV-2 Rapid Antigen Test Nasal. The test will be available in countries accept
Wide-Moat Stocks On Sale - The February 2021 Heat Map
09:40pm, Thursday, 28'th Jan 2021
Our three-step process focuses on wide-moat stocks (as per Morningstar's rating).
Roche renews partnership with Sysmex to deliver haematology testing solutions
01:03am, Monday, 25'th Jan 2021
Basel, 25 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that, on 14 December, 2020, it signed a Global Business Partnership Agreement* (GBP) with Sysmex. Under this new framework,
Basel, 25 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from two identically designed global phase III studies, TENAYA and LUCERNE, evaluating its investig
AbbVie, Roche, Glaxo Are Experts at Product Launches
06:08pm, Thursday, 21'st Jan 2021
Investors considering pharmaceutical and biotechnology companies might want to factor in one important piece of data into their analysis: A high percentage of new products fail to reach sales forecast
Roche's (RHHBY) Esbriet sNDA Gets Priority Review From FDA
10:32am, Thursday, 21'st Jan 2021
The FDA accepts Roche's (RHHBY) sNDA for Esbriet under a priority review to treat unclassifiable interstitial lung disease. A verdict from the regulatory body is awaited in May 2021.
FDA Grants Priority Review to Genentech's Esbriet (pirfenidone) for Unclassifiable Interstitial Lung Disease
01:00am, Thursday, 21'st Jan 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the com
Roche Annual General Meeting 2021: Exercising of shareholder rights via the independent proxy
01:00am, Monday, 18'th Jan 2021
Basel, 18 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that unfortunately it will not be possible for shareholders to attend the Annual General Meeting in person owing to the ongo
Invitae Nabs Bristol Myers Squibb, J&J, Novartis, and Roche for Acute Myeloid Leukemia Project
02:08pm, Thursday, 14'th Jan 2021
Those are some solid endorsements.
Roche confirms US government agreement to purchase additional doses of Regeneron's casirivimab and imdevimab
05:55pm, Tuesday, 12'th Jan 2021
Basel, 12 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed that the U.S. Department of Health and Human Services (HHS) and the Department of Defense (DOD) will purchase additional sup
Basel, 12 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present updated overall survival (OS) data from the Phase III IMbrave150 study evaluating Tecentriq® (atezolizumab) in combination wit
Roche launches two digital pathology image analysis algorithms for precision patient diagnosis in breast cancer
01:03am, Monday, 11'th Jan 2021
Basel, 11 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the CE-IVD launch of its automated digital pathology algorithms, uPath HER2 (4B5) image analysis and uPath Dual ISH image an
Basel, 11 January 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC) has approved Xofluza® (baloxavir marboxil) for the treatment of uncomplicated influenza
3 Biotech Technological Developments to Watch Out For in 2021
09:47am, Thursday, 07'th Jan 2021
Here we discuss three booming technological developments in the biotech sector, which can capture investor attention in 2021
Roche's (RHHBY) Immunotherapy Gets Breakthrough Therapy Status
12:02pm, Tuesday, 05'th Jan 2021
Roche's (RHHBY) tiragolumab in combination with Tecentriq wins Breakthrough Therapy designation for the first-line treatment of patients with metastatic non-small cell lung cancer.
